L'analyse de l'étude du CEPMB, parallèlement à celle de IMS health, donne des indications nettes que le prix des génériques au Canada présente un meilleur rapport qualité prix que les médicaments de marque lorsque la comparaison est faite dans le même groupe de pays.
When the PMPRB did use the same countries, brand-name multiple-source drugs were found to be between 39% and 54% higher in Canada than the median prices in the other nine countries studied (0935) I will refer members to appendix A of our brief, which outlines our concerns and our analysis of the PMPRB study in detail. This analysis of the PMPRB study, when combined with the IMS health study, provides strong evidence that generic prices in Canada are actually a better value than brand-name prices when both are compared within the same group of countries.